Trial Profile

Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin (Primary) ; Tumour cells apoptosis factor (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

06 Mar 2026 Planned End Date changed from 1 Jan 2026 to 1 Jan 2027.
06 Mar 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.
06 Jun 2023 Study design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com